Helping Young People With Testicular Cancer Using Virtual and Extended Reality

Starting soon · Not applicable

Conditions studied: Testicular Cancer, Testis Cancer, AYA Cancer Survivors, Survivor Patients

In brief

TRANSCEND-XR is a European research project designed to better support adolescents and young adults who have been cured of testicular cancer. Even after treatment has ended, many young people continue to face physical, psychological, or social difficulties that are often poorly understood and insufficiently addressed. The project aims to develop an innovative digital tool using extended reality (XR) to help these young people better understand the potential long-term effects of the disease and its treatments, recognize signs that require medical attention, and become more active participants in their own health follow-up. TRANSCEND-XR first includes a pilot phase to test feasibility and improve the tool, followed by a larger clinical study comparing its use with usual medical follow-up. Researchers will assess, in particular, its impact on patients' knowledge, quality of life, and ability to seek help. The ultimate goal is to sustainably improve information, autonomy, and well-being among young survivors of testicular cancer through a digital approach tailored to their needs and daily practices.

Key facts

Study ID

NCT07571499

Run by

Gustave Roussy, Cancer Campus, Grand Paris

People needed

245

Starts

2027-01-04

Expected to finish

2029-06-30

Last updated by the study team

2026-05-06

Who can join

Age: 15 and older, up to 39. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Any person assigned male at birth who is diagnosed with stage I-III TC (germ cell tumour of the testicles).
• Aged between 15 and 39 years at the time of study inclusion.
• Completed curative treatment comprising of at least one standard treatment modality (surgery, chemotherapy and/or radiotherapy) for treatment of their cancer. A maximum of 9 months from the end of curative treatment will be allowed.
• Permitted treatment modalities:
• Localised disease: orchiectomy with or without chemotherapy and/or radiotherapy.
• Metastatic disease: orchiectomy and chemotherapy or radiotherapy or retroperitoneal surgery, or a combination of aforementioned treatments. First-line treatment only allowed.
• Willing and able to provide a valid and signed informed consent and/or assent, as appropriate.
• ECOG performance status 0-2.
• Patients accept to use personal smartphone
• Patients able to read and understand the local language

You may not qualify if…

• Non-testicular germ cell tumours (e.g., mediastinal primary or retroperitoneal primary tumours).
• Non-germ cell TC.
• Previous chemotherapy, radiotherapy, or surgery for TC other than that allowed in IC 4.
• History of contralateral TC.
• Any illness that would prevent the AYA TC survivor from giving a valid and signed informed consent, as assessed by the investigator.
• Any illness that might be exacerbated by the use of an XR digital tool, as assessed by the investigator, including history of severe motion sickness, brain lesions and epilepsy.
• Uncontrolled medical condition such as uncontrolled infection, uncontrolled diabetes mellitus or cardiac disease (including but not limited to grade 2 or higher cardiac failure, arrythmia, unstable angina, history of myocardial infract in the 6 months which, in the opinion of the treating physician, would influence the assessment of long-term side effect of TC treatment.
• AYA TC survivors with a "currently active" second malignancy other than non-melanoma skin cancers, superficial non-invasive (pTa or pTis) TCC of the bladder, or intratubular germ cell neoplasia. Patients are not considered to have a "currently active" malignancy if they have completed therapy and are free of disease for ≥ 3 years.
• Chemotherapy or radiotherapy for malignant disease other than TC within the past 3 years.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.